Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial
Vaduganathan M, Sattar N, Fitchett D, George J, Ofstad A, Verma S, Mattheus M, Wanner C, Inzucchi, Zinman B, Butler J. Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s18-s19. DOI: 10.1055/s-0041-1727336.Peer-Reviewed Original ResearchInsulin dose reductionType 2 diabetesEMPA-REGCardiovascular diseaseDose reductionDiabetesPatientsDiseaseTrials